Lifecore Historical Cash Flow

LFCR Stock   7.50  0.06  0.81%   
Analysis of Lifecore Biomedical cash flow over time is an excellent tool to project Lifecore Biomedical future capital expenditures as well as to predict the amount of cash needed to cover cost of sales, R&D expenses or production expansions. Investors should almost always look for trends in cash flow indicators such as Depreciation of 8.2 M or Capital Expenditures of 16.4 M as it is a great indicator of Lifecore Biomedical ability to facilitate future growth, repay debt on time or pay out dividends.
 
Covid
Financial Statement Analysis is much more than just reviewing and examining Lifecore Biomedical latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Lifecore Biomedical is a good buy for the upcoming year.
  
Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Lifecore Biomedical. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in main economic indicators.
To learn how to invest in Lifecore Stock, please use our How to Invest in Lifecore Biomedical guide.

About Lifecore Cash Flow Analysis

The Cash Flow Statement is a financial statement that shows how changes in Lifecore balance sheet and income statement accounts affect cash and cash equivalents. It breaks the analysis down to operating, investing, and financing activities. One of the most critical aspects of the cash flow statement is liquidity, which is the degree to which Lifecore's non-liquid assets can be easily converted into cash.

Lifecore Biomedical Cash Flow Chart

At this time, Lifecore Biomedical's Change To Liabilities is relatively stable compared to the past year.

Begin Period Cash Flow

The amount of cash a company has at the beginning of a financial reporting period. It serves as the starting point for calculating the period's cash flow from operations, investing, and financing activities.

Capital Expenditures

Capital Expenditures are funds used by Lifecore Biomedical to acquire physical assets such as property, industrial buildings or equipment. This type of outlay is used by management to increase the scope of Lifecore Biomedical operations. These expenditures can include everything from repairing an office equipment, building a brand new facility, or writing new software.

Stock Based Compensation

Compensation provided to employees in the form of equity or options to purchase company stock. This type of compensation is used to align the interests of employees and shareholders.

Dividends Paid

The total amount of dividends that a company has paid out to its shareholders over a specific period.
Most accounts from Lifecore Biomedical's cash flow statement are interrelated and interconnected. However, analyzing cash flow statement accounts one by one will only give a small insight into Lifecore Biomedical current financial condition. On the other hand, looking into the entire matrix of cash flow statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Lifecore Biomedical. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in main economic indicators.
To learn how to invest in Lifecore Stock, please use our How to Invest in Lifecore Biomedical guide.At this time, Lifecore Biomedical's Change To Liabilities is relatively stable compared to the past year.

Lifecore Biomedical cash flow statement Correlations

-0.050.660.620.62-0.72-0.46-0.590.440.7-0.210.130.56-0.530.170.47-0.19-0.230.49
-0.050.170.3-0.5-0.190.19-0.35-0.140.34-0.82-0.670.180.310.19-0.130.06-0.24-0.22
0.660.170.610.58-0.71-0.74-0.580.820.76-0.29-0.070.35-0.290.670.32-0.46-0.740.23
0.620.30.610.19-0.38-0.3-0.30.280.49-0.28-0.220.51-0.220.170.7-0.11-0.380.2
0.62-0.50.580.19-0.6-0.61-0.310.630.580.250.370.0-0.570.360.13-0.29-0.30.54
-0.72-0.19-0.71-0.38-0.60.670.66-0.68-0.880.57-0.06-0.260.6-0.58-0.080.320.53-0.63
-0.460.19-0.74-0.3-0.610.670.42-0.94-0.560.13-0.42-0.080.56-0.55-0.280.550.54-0.44
-0.59-0.35-0.58-0.3-0.310.660.42-0.3-0.720.560.28-0.370.19-0.12-0.110.140.12-0.16
0.44-0.140.820.280.63-0.68-0.94-0.30.57-0.120.350.08-0.470.740.19-0.6-0.730.38
0.70.340.760.490.58-0.88-0.56-0.720.57-0.51-0.090.2-0.440.480.09-0.27-0.470.47
-0.21-0.82-0.29-0.280.250.570.130.56-0.12-0.510.42-0.320.06-0.290.040.060.3-0.12
0.13-0.67-0.07-0.220.37-0.06-0.420.280.35-0.090.42-0.25-0.45-0.1-0.04-0.350.20.43
0.560.180.350.510.0-0.26-0.08-0.370.080.2-0.32-0.250.08-0.010.53-0.2-0.15-0.23
-0.530.31-0.29-0.22-0.570.60.560.19-0.47-0.440.06-0.450.08-0.35-0.35-0.210.25-0.92
0.170.190.670.170.36-0.58-0.55-0.120.740.48-0.29-0.1-0.01-0.35-0.02-0.2-0.960.31
0.47-0.130.320.70.13-0.08-0.28-0.110.190.090.04-0.040.53-0.35-0.020.15-0.170.11
-0.190.06-0.46-0.11-0.290.320.550.14-0.6-0.270.06-0.35-0.2-0.21-0.20.150.230.17
-0.23-0.24-0.74-0.38-0.30.530.540.12-0.73-0.470.30.2-0.150.25-0.96-0.170.23-0.2
0.49-0.220.230.20.54-0.63-0.44-0.160.380.47-0.120.43-0.23-0.920.310.110.17-0.2
Click cells to compare fundamentals

Lifecore Biomedical Account Relationship Matchups

Lifecore Biomedical cash flow statement Accounts

201920202021202220232024 (projected)
Change To Inventory(12.2M)(3.4M)(6.0M)(6.1M)862K905.1K
Change In Cash(1.8M)(912K)742K348K(10.6M)(10.1M)
Free Cash Flow(28.7M)(43.7M)(8.8M)(52.5M)(18.1M)(17.2M)
Change In Working Capital(27.7M)8.9M(6.6M)(6.7M)(3.8M)(4.0M)
Begin Period Cash Flow3.2M1.5M553K1.3M19.1M11.1M
Other Cashflows From Financing Activities145.4M(10.9M)73.5M(1.6M)4.8M4.5M
Depreciation18.8M19.9M17.9M17.8M8.9M8.2M
Other Non Cash Items(2.9M)33.0M23.5M66.0M(20.9M)(19.9M)
Capital Expenditures44.7M26.7M23.8M28.1M17.9M16.4M
Total Cash From Operating Activities16.0M(17.0M)15.0M(24.4M)(217K)(206.2K)
Net Income(38.2M)(32.7M)(97.4M)(97.2M)9.3M9.8M
Total Cash From Financing Activities79.0M40.0M(3.4M)(57.0M)7.5M7.9M
End Period Cash Flow1.5M553K1.3M1.6M8.5M10.9M
Sale Purchase Of Stock(700K)(212K)(405K)(789K)(152K)(159.6K)
Stock Based Compensation2.4M3.3K2.6M2.6K6.2M6.5M
Change To Account Receivables(6.6M)5.8M(6.1M)(6.3M)(2.4M)(2.5M)
Net Borrowings41.8M7.5M(55.4M)19.4M17.5M14.9M
Total Cashflows From Investing Activities(23.9M)(10.9M)81.8M(4.2M)(4.8M)(5.0M)
Change To Operating Activities(7.4M)11.7M(3.8M)4.5M5.2M5.4M
Change To Netincome29.7M18.9M61.7M32.2M37.0M31.8M
Change To Liabilities(1.4M)(5.2M)9.3M19.2M22.1M23.2M

Pair Trading with Lifecore Biomedical

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Lifecore Biomedical position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Lifecore Biomedical will appreciate offsetting losses from the drop in the long position's value.

Moving together with Lifecore Stock

  0.82VTRS ViatrisPairCorr
  0.82ESPR Esperion TherapeuticsPairCorr

Moving against Lifecore Stock

  0.91RDY Dr Reddys LaboratoriesPairCorr
  0.9LLY Eli Lilly Sell-off TrendPairCorr
  0.87TAK Takeda PharmaceuticalPairCorr
  0.84MRK Merck Company Fiscal Year End 6th of February 2025 PairCorr
  0.83PFE Pfizer Inc Aggressive PushPairCorr
The ability to find closely correlated positions to Lifecore Biomedical could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Lifecore Biomedical when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Lifecore Biomedical - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Lifecore Biomedical to buy it.
The correlation of Lifecore Biomedical is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Lifecore Biomedical moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Lifecore Biomedical moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Lifecore Biomedical can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching

Additional Tools for Lifecore Stock Analysis

When running Lifecore Biomedical's price analysis, check to measure Lifecore Biomedical's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Lifecore Biomedical is operating at the current time. Most of Lifecore Biomedical's value examination focuses on studying past and present price action to predict the probability of Lifecore Biomedical's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Lifecore Biomedical's price. Additionally, you may evaluate how the addition of Lifecore Biomedical to your portfolios can decrease your overall portfolio volatility.